Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Co., Ltd. reported a significant decline in its financial performance for the year ended December 31, 2024, with revenue dropping by 42.4% to approximately RMB326.0 million and a substantial increase in net loss attributable to equity shareholders to approximately RMB188.8 million. The company’s gross profit margin also decreased to 49.9%, and the board decided not to recommend any final dividend for the year, reflecting the challenging market conditions and operational difficulties faced by the company.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd., incorporated in the Cayman Islands, operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products.
YTD Price Performance: -65.62%
Average Trading Volume: 428,347
Technical Sentiment Signal: Buy
Current Market Cap: HK$202.2M
For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.